Enhabit, Inc. (EHAB) 

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.

Show less

Over the last 12 months, insiders at Enhabit, Inc. have bought $183,700 and sold $5,586 worth of Enhabit, Inc. stock.

On average, over the past 5 years, insiders at Enhabit, Inc. have bought $837,317 and sold $5,586 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Bolton Jeffrey (director) — $165,700. Hoeflinger Erin (director) — $18,000.

The last purchase of 10,000 shares for transaction amount of $83,300 was made by Bolton Jeffrey (director) on 2024‑05‑17.